Abstract
In China, the vaccination strategy against pertussis is started from 3 months of age, with no booster dose used after the booster given at two years. Despite a high vaccination coverage, pertussis has been increasingly reported since the last decade. This study evaluates the prevalence of serum anti-pertussis toxin (PT) IgG antibodies in adults at childbearing age and infants before the age of primary immunization in Beijing, China. A total of 1175 serum samples randomly selected from individuals who attended an annual health examination at the Sixth Medical Center of the PLA General Hospital, Beijing, in 2019, was included. The geometric mean concentration (GMC) and median concentration of anti-PT IgG antibodies among adults aged 20–39 years were 3.81 IU/mL and 3.24 IU/mL, and the corresponding concentrations were 1.72 IU/mL and 1.43 IU/mL among infants under 3 months of age. The seroprevalence of PT IgG antibodies ≥ 40 IU/mL in adults and infants was 2.0% (15/735) and 1.1% (5/440). In total, 65.99% (485/735) of adults and 83.41% (367/440) of infants had non-detectable pertussis-specific antibodies (<5 IU/mL). Our results showed that the majority of adults at a reproductive age and young infants are vulnerable to pertussis, suggesting that booster vaccinations in adults should be considered in this country.
Highlights
Whooping cough, or pertussis, is an acute respiratory infection and is mainly caused by the Gram-negative bacillus Bordetella pertussis
A recent cross-sectional study conducted in Beijing, China, compared the seroprevalence of anti-pertussis toxin (PT) IgG antibodies in samples collected during
The geometric mean concentration (GMC) and median concentration of anti-PT IgG antibodies among adult subjects were 3.81 IU/mL and 3.24 IU/mL
Summary
Pertussis, is an acute respiratory infection and is mainly caused by the Gram-negative bacillus Bordetella pertussis. The Chinese vaccination strategy is primarily administered with three doses of DTaP vaccines at the age of 3, 4, and 5 months, with a booster dose given at 18–24 months. After the booster dose at two years of age, no booster dose is given This vaccination strategy has remained unchanged since the 1980s. Most adults at childbearing age and young infants may not have enough protective antibodies such as anti-pertussis toxin (PT) IgG antibodies. A recent cross-sectional study conducted in Beijing, China, compared the seroprevalence of anti-PT IgG antibodies in samples collected during. Vaccines 2022, 10, 84 as anti-pertussis toxin (PT) IgG antibodies. A recent cross-sectional study conducted in Beijing, China, compared the seroprevalence of anti-PT IgG antibodies in samples cololyIwii(ytaitcneegn
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
